288 related articles for article (PubMed ID: 18190258)
1. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
[TBL] [Abstract][Full Text] [Related]
2. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.
Abdulle S; Hagberg L; Gisslén M
HIV Med; 2005 May; 6(3):164-9. PubMed ID: 15876282
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
4. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
5. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection.
Enting RH; Prins JM; Jurriaans S; Brinkman K; Portegies P; Lange JM
Clin Infect Dis; 2001 Apr; 32(7):1095-9. PubMed ID: 11264039
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
[TBL] [Abstract][Full Text] [Related]
7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
8. [Cerebrospinal fluid viral load in HIV-1 positive hemophilic patients treated with HAART].
Corti ME; Villafañe MF; Baré P; Alves Rosa F; Cermelj M; Candela M; Pérez Bianco R; Tezanos Pinto M
Medicina (B Aires); 2001; 61(6):821-4. PubMed ID: 11808421
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
11. Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection.
Cepok S; von Geldern G; Nolting T; Grummel V; Srivastava R; Zhou D; Hartung HP; Adams O; Arendt G; Hemmer B
Ann Neurol; 2007 Nov; 62(5):458-67. PubMed ID: 17703460
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.
Cinque P; Bestetti A; Morelli P; Presi S
J Neurovirol; 2000 May; 6 Suppl 1():S95-S102. PubMed ID: 10871772
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.
Ellis RJ; Childers ME; Zimmerman JD; Frost SD; Deutsch R; McCutchan JA;
J Infect Dis; 2003 Jun; 187(11):1818-21. PubMed ID: 12751041
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
16. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
Günthard HF; Havlir DV; Fiscus S; Zhang ZQ; Eron J; Mellors J; Gulick R; Frost SD; Brown AJ; Schleif W; Valentine F; Jonas L; Meibohm A; Ignacio CC; Isaacs R; Gamagami R; Emini E; Haase A; Richman DD; Wong JK
J Infect Dis; 2001 May; 183(9):1318-27. PubMed ID: 11294662
[TBL] [Abstract][Full Text] [Related]
17. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
Gisslén M; Fuchs D; Svennerholm B; Hagberg L
J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104
[TBL] [Abstract][Full Text] [Related]
19. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
McArthur JC; McDermott MP; McClernon D; St Hillaire C; Conant K; Marder K; Schifitto G; Selnes OA; Sacktor N; Stern Y; Albert SM; Kieburtz K; deMarcaida JA; Cohen B; Epstein LG
Arch Neurol; 2004 Nov; 61(11):1687-96. PubMed ID: 15534180
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
